Royalty Pharma (NASDAQ:RPRX) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Royalty Pharma (NASDAQ:RPRX) issued its earnings results on Wednesday. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.05, Zacks reports. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%.The company had revenue of $674.14 million for the quarter, compared to the consensus estimate of $758.93 million.

Here are the key takeaways from Royalty Pharma’s conference call:

• Royalty receipts grew 14% year over year in the second quarter, while portfolio receipts increased 6% to $773 million and portfolio cash flow reached $736 million, reflecting approximately 95% cash conversion.
• Royalty Pharma raised its 2026 guidance for the second consecutive quarter, now forecasting portfolio receipts of $3.4 billion to $3.5 billion and royalty-receipt growth of approximately 7% to 10%, despite expected headwinds from PROMACTA, TYSABRI biosimilars and the IRA.
• The company acquired a royalty on AstraZeneca’s cliramitug for up to $425 million, gaining a 3.75% worldwide sales royalty on a potential first-in-class treatment for transthyretin amyloid cardiomyopathy with projected peak royalties of approximately $110 million to $190 million.
• Royalty Pharma cited continued progress across its pipeline, including regulatory submissions and approvals, with 19 development-stage therapies and approximately $2 billion of potential peak royalties in the late-stage pipeline; key trial readouts are expected through 2027.
• The company ended June with $812 million in cash, $9.2 billion of investment-grade debt and leverage of 2.8 times adjusted EBITDA, while maintaining more than $4 billion of financial flexibility and returning approximately $367 million to shareholders in the first half.

Royalty Pharma Trading Down 0.9%

RPRX traded down $0.51 on Friday, hitting $56.75. The company had a trading volume of 2,227,520 shares, compared to its average volume of 3,545,464. The business’s fifty day simple moving average is $56.45 and its 200 day simple moving average is $50.42. The company has a quick ratio of 2.66, a current ratio of 2.80 and a debt-to-equity ratio of 0.88. Royalty Pharma has a 12-month low of $34.08 and a 12-month high of $60.44. The company has a market cap of $32.68 billion, a PE ratio of 39.22, a PEG ratio of 10.11 and a beta of 0.43.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.7%. Royalty Pharma’s dividend payout ratio (DPR) is presently 63.95%.

Analysts Set New Price Targets

Several equities analysts have recently commented on RPRX shares. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. UBS Group lifted their price target on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Citigroup boosted their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Bank of America restated a “buy” rating on shares of Royalty Pharma in a research report on Wednesday. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Royalty Pharma in a report on Thursday. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Royalty Pharma presently has a consensus rating of “Buy” and an average target price of $60.86.

Insider Buying and Selling

In other news, EVP Marshall Urist sold 9,099 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $55.88, for a total value of $508,452.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $56.52, for a total value of $5,652,000.00. Following the completion of the transaction, the executive vice president owned 459,399 shares of the company’s stock, valued at approximately $25,965,231.48. This trade represents a 17.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 393,009 shares of company stock valued at $21,601,827. 18.84% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RPRX. Compound Planning Inc. boosted its stake in shares of Royalty Pharma by 21.7% during the 4th quarter. Compound Planning Inc. now owns 10,618 shares of the biopharmaceutical company’s stock worth $410,000 after purchasing an additional 1,896 shares during the period. Corient Private Wealth LLC lifted its stake in Royalty Pharma by 26.8% in the fourth quarter. Corient Private Wealth LLC now owns 154,922 shares of the biopharmaceutical company’s stock worth $5,986,000 after purchasing an additional 32,766 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its position in shares of Royalty Pharma by 25.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 17,177 shares of the biopharmaceutical company’s stock valued at $664,000 after buying an additional 3,452 shares during the period. Achmea Investment Management B.V. purchased a new position in shares of Royalty Pharma during the fourth quarter valued at approximately $1,321,000. Finally, Delta Global Management LP bought a new position in shares of Royalty Pharma during the fourth quarter valued at approximately $1,712,000. Institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.